logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

Melanoma: less ipilimumab, more nivolumab improves safety

CheckMate 511 shows similar efficacy, fewer AEs with NIVO3/IPI1 vs NIVO1/IPI3.